JRCT ID: jRCT2080224980
Registered date:10/12/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 12/02/2020 |
Target sample size | 372 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania,null |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : amcenestrant Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : fulvestrant, anastrozole, letrozole, exemestane, tamoxifen Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy efficacy efficacy efficacy efficacy efficacy pharmacokinetics efficacy efficacy efficacy safety |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04059484,2018-004593-98,JapicCTI-195068 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation |